Hawaii Biotech Receives Funding From the Pediatric Dengue Vaccine ... ( HONOLULU April 7 2008 /- Hawaii B...)

Hawaii Biotech Receives Funding From the Pediatric Dengue Vaccine Initiative

Date:4/7/2008

HONOLULU, April 7, 2008 /PRNewswire/ -- Hawaii Biotech announced today that it has received a grant from the Pediatric Dengue Vaccine Initiative (PDVI) to support the manufacture of Hawaii Biotech's dengue vaccine for eventual testing in clinical trials. Hawaii Biotech emphasized that it has not yet initiated regulatory filing for its dengue vaccine formulation.

Dengue is a mosquito-borne illness, prevalent in tropical and subtropical countries throughout the world. Approximately 3.5 billion people live in endemic countries and about 100 million people are infected with dengue every year according to recent estimates published by the PDVI. Infection by any one of the four dengue viruses can lead to dengue fever, which can progress to a life-threatening hemorrhagic fever and shock syndrome.

"PDVI conducted a thorough, independent evaluation of Hawaii Biotech's dengue vaccine program and believes their vaccine represents a promising candidate worthy of further development, which should lead to clinical evaluation," stated Dr. Harold Margolis, Director of the PDVI. "The Hawaii Biotech vaccine is the only subunit vaccine candidate against dengue that has advanced this far into pre-clinical development. We see the Hawaii Biotech vaccine as an important part of our portfolio of vaccines in our efforts to control this global public health problem."

"We appreciate the opportunity to collaborate with PDVI as we work to prevent disease caused by these debilitating viruses," said Dr. Elliot Parks of Hawaii Biotech. "We are also excited to be able to be part of an effort to control this disease, which occurs primarily in countries less developed than the United States."

PDVI is located at the International Vaccine Institute (IVI) in Seoul, Korea. IVI is the world's only international organization solely dedicated to vaccine research and development. Dr. John Clemens, Director General of IVI, commented, "The IVI is committed to ensuring availab
'/>"/>

0

GOOD

Page: 1 2
Related biology technology :

1. Aton Pharma Introduces Expanded Distribution of Lacrisert(R) (hydroxypropyl cellulose ophthalmic insert) at Hawaiian Eye
2. Raven biotechnologies and Bioprocessing Technology Institute Announce Collaboration to Advance Discovery of Stem Cell Antibodies
3. EnzySurge, Maker of DermaStream(TM), Establishes a US Office in the Virginia Biotech Commercialization Center
4. Genetic Engineering & Biotechnology News reports on cancer biomarkers
5. Biotech Avoids Fall Out From Tough Quarter for Capital Markets
6. HighPoint Solutions Selected by Global Biotechnology Company to Provide Master Data Management Solution
7. Champions Biotechnology, Inc. Appoints New Board Members and Forms Management Team
8. Chicago Biotech Career Fair to Draw Hundreds of Bioscience Candidates and Top Employers
9. China Kangtai Cactus Biotech, Inc. Obtains $500,000 Equity Financing
10. Tiens Biotech Group (USA) Reports Fourth Quarter and Twelve-Month Results
11. deCODE genetics to Webcast Presentation at 15th Annual Future Leaders in the Biotech Industry Conference

Post Your Comments:

Hawaii Biotech Receives Funding From the Pediatric Dengue Vaccine ...( HONOLULU April 7 2008 /- Hawaii B...)